Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs AST SpaceMobile Inc (ASTS) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade

AST SpaceMobile IncTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs AST SpaceMobile Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.03B), while AST SpaceMobile Inc trades at $72.3 (market cap $20.54B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and AST SpaceMobile Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.

	ALNY	ASTS
Market Cap	$29.03B	$20.54B
Sector	Health	Media
52-Week High	$491.22	$133.09
52-Week Low	$205.48	$36.91
Enterprise Value	$26.99B	$21.25B

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $219.20, down 1.43% amid bearish technical signals and recent earnings volatility. The stock faces near-term pressure from a Q2 2026 EPS miss and lowered 2026 sales guidance, but maintains strong fundamentals with 2025 revenue of $3.71B and net income of $313.75M. Analyst consensus remains bullish with a $370.07 price target, though multiple law firms are investigating potential securities fraud as reported by PRNewsWire and GlobeNewsWire in early August 2026.

Outlook is mixed: robust revenue growth and high profitability margins support long-term potential, but legal uncertainties and recent earnings disappointments pose significant risks. The stock's current valuation (P/E 38.19) reflects growth expectations, yet investor caution is warranted given technical bearishness and ongoing investigations.

AST SpaceMobile Inc

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

ALNY

New report analyzes 1,350+ precision medicine deals from 2019-2026, revealing market trends and deal structures.Researchandmarkets.Com · 4 days agoNeutral View details →

ASTS

SpaceX shares fall 5% after post-IPO rally fades amid heavy AI spending concerns24/7 Wall Street · 19 hours agoBearish AST SpaceMobile posts wider Q2 loss, revenue below estimates but confirms 2026 guidance and expands satellite networkProactive Investors · 22 hours agoBearish AST SpaceMobile Q2 revenue rises but loss widens; Cantor raises price target to $90Andrew Wynn · 22 hours agoNeutral View details →

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

About AST SpaceMobile Inc

AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.